Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD) presented at ACC 2025

Posted on by sHq_LoGiNz

Semaglutide 1 mg demonstrated statistically significant and superior improvement in maximum walking distance by 13% over placebo in adults with type 2 diabetes and symptomatic PAD1 Based on STRIDE trial data, presented at the American College of Cardiology’s (ACC) Annual Scientific…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.